Case Page

 

Case Status:    DISMISSED    
On or around 05/16/2018 (Notice of voluntarily dismissal)

Filing Date: February 22, 2018

According to the Complaint, Alliqua BioMedical, Inc. is a provider of wound care solutions. The Company operates in commercial wound care segment, which consists of approximately five product categories, such as Wound Bed Preparation & Stimulation; Human Biologics; Antimicrobial Protection; Exudate Management, and Contract Manufacturing. Alliqua has a suite of wound care solutions that enable surgeons, clinicians, and wound care practitioners to address the challenges in chronic and acute wounds. The Company has built its portfolio through its hydrogel technology platform, targeted acquisitions, and through licensing and distribution agreements. Alliqua’s contract manufacturing business provides custom hydrogels to the original equipment manufacturer (OEM) market.

On January 5, 2018, Alliqua issued a press release announcing that it had entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) by and among the Company and Celularity Inc.

The Complaint alleges that on January 29, 2018, in order to convince Alliqua stockholders to vote in favor of the Proposed Transaction, Defendants authorized the filing of a materially incomplete and misleading Preliminary Proxy Statement on a Schedule 14A (the “Proxy”) with the SEC, in violation of Sections 14(a) and 20(a) of the Exchange Act. The Complaint alleges that in particular, the Proxy contains materially incomplete and misleading information concerning: (i) the valuation analyses conducted by the Company’s financial advisor, Cowen and Company, LLC (“Cowen”); and (ii) the background process leading up to the Proposed Transaction.

This case was dismissed as moot on April 4, 2018.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Major Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: ALQA
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Delaware
DOCKET #: 18-CV-00301
JUDGE:
DATE FILED: 02/22/2018
CLASS PERIOD START: 01/05/2018
CLASS PERIOD END: 02/22/2018
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Cooch & Taylor, P.A.
    The Brandywine Building; 1000 West Street, 10th Floor, Cooch & Taylor, P.A., DE 19801
    302.984.3800 302.984.3939 ·
  2. Monteverde & Associates PC
    350 Fifth Avenue, 59th Floor, Monteverde & Associates PC, NY 10118
    (212) 971-1341 ·
No Document Title Filing Date